Sarepta Therapeutics Announces Call for Applications for the 6th ...

... announced our submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for casimersen ...

Gene Therapy Town Hall -- PPMD 2023 Annual Conference

Gene Therapy Town Hall (AAV ... Sarepta Therapeutics – Panel Discussion and Q & A. ... Open App. This content isn't available. Gene ...

Sarepta scraps a Duchenne drug as gene therapy sales rise

5. Sarepta on Nov. 6 reported its gene therapy ... call Wednesday. ... Osteal Therapeutics Announces Positive 12-Month Results from the APEX ...

Sarepta Therapeutics Announces Second Quarter 2024 Financial ...

... application (MAA) for the treatment of ... 5:15-6:15 PM CET ... To report SUSPECTED ADVERSE REACTIONS, contact Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Recipients of the 6th Annual ...

Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year 9/7 ...

Endpoints News – Biotech and pharma business news, with a focus ...

Biotech and pharma business news, with a focus on the science, people and money that drive the industry.

Could Gene Therapy Be the Answer? Exploring SRP-9001 - YouTube

Open App. This content isn't available ... Sarepta Therapeutics announces FDA approval ... 6:41 · Go to channel · Former FDA commissioner ...

Press Releases | Sarepta Therapeutics, Inc. - Investor Relations

Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA ... Sarepta Therapeutics to Host Conference Call to Discuss Regulatory Update for ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). 08/31/20 6:30 PM EDT. CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) ...

Sarepta Therapeutics Announces Second Quarter 2023 Financial ...

... therapy programs. Research and development ... Age at study entry was 6 months to 19 years. ... Media Contact: Tracy Sorrentino , 617-301-8566 tsorrentino@sarepta.

Sarepta Therapeutics Announces Positive Vote from U.S. FDA ...

Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 ... applications. Actual results could ... Investor Contact: Ian ...

Sarepta Therapeutics Announces Call for Applications for the 6th ...

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program Click ...

Press Releases | Sarepta Therapeutics, Inc. - Investor Relations

6/30/20, Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer ; 6/26/20 ...

Sarepta Therapeutics Announces Fourth Quarter and Full-Year ...

Sarepta achieved these stellar results by prioritizing our patients and without taking a single price increase in over 6 years,” said Doug Ingram , Sarepta's ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). 12/31/20 6:30 PM EST. CAMBRIDGE, Mass., Dec. 31, 2020 (GLOBE NEWSWIRE) ...

Press Release - Investor Relations - Sarepta Therapeutics

Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). 07/31/23 6:08 PM EDT. CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). 06/30/23 6:20 PM EDT. CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). 03/31/23 6:25 PM EDT. CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq ...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). 04/28/23 6:15 PM EDT. CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 28, ...